• Assets in clinical
    development
    5
  • Innovative therapies in
    preclinical or clinical
    development
    10+
  • Partnered programs
    8
RICH PIPELINE OF
BREAKTHROUGH THERAPEUTICS
  • Molecule: BSI-045B
    Modality / Target:
    mAb, TSLP
    Severe Asthma
    Partner: CTTQ - China
    • Preclinical
      Phase I
      Phase II
      Phase III
    Atopic Dermatitis
    • Preclinical
      Phase I
      Phase II
      Phase III
    COPD
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-502
    Modality / Target:
    bsAb, targets undisclosed
    Auto-Immune
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-038
    Modality / Target:
    mAb, CD40
    Solid Tumors
    Partner: CTTQ - China
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-060T
    Modality / Target:
    mAb, Siglec-15
    Solid Tumors
    Partner: PYXIS - Ex China
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-585
    Modality / Target:
    bsAb, PD1/ILT4
    Solid Tumors
    Partner: Celldex - Ex China
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-04702
    Modality / Target:
    ADC, TROP2
    Solid Tumors
    Partner: OBI - Ex China
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-082
    Modality / Target:
    mAb, SIRPα
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-001
    Modality / Target:
    mAb, HER2
    Solid Tumors
    Partner: ANKEBIO - China
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-075
    Modality / Target:
    mAb, PVRIG
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-500
    Modality / Target:
    bsAb, targets undisclosed
    Solid Tumors
    Partner: CTTQ - China
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-729
    Modality / Target:
    bsAb, targets undisclosed
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-712
    Modality / Target:
    ADC, LIV-1
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
  • Molecule: BSI-709
    Modality / Target:
    ADC, CDH6
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
Copyright © 2022. Biosion All rights reserved. 苏ICP备2022027163号
  • Assets in clinical
    development
    5
  • Innovative therapies in
    preclinical or clinical
    development
    10+
  • Partnered programs
    8
Filter by:
  • All categories
  • Immunology
  • Oncology
  • BSI-045B
    Modality / Target:
    mAb, TSLP
    MORE
    Severe Asthma
    • Preclinical
      Phase I
      Phase II
      Phase III
    Partner
    CTTQ - China
    Atopic Dermatitis
    • Preclinical
      Phase I
      Phase II
      Phase III
    COPD
    • Preclinical
      Phase I
      Phase II
      Phase III
  • BSI-502
    Modality / Target:
    bsAb, targets undisclosed
    MORE
    Auto-Immune
    • Preclinical
      Phase I
      Phase II
      Phase III
  • BSI-038
    Modality / Target:
    mAb, CD40
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
    Partner
    CTTQ - China
  • BSI-060T
    Modality / Target:
    mAb, Siglec-15
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
    Partner
    PYXIS - Ex China
  • BSI-585
    Modality / Target:
    bsAb, PD1/ILT4
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
    Partner
    Celldex - Ex China
  • BSI-04702
    Modality / Target:
    ADC, TROP2
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
    Partner
    OBI - Ex China
  • BSI-082
    Modality / Target:
    mAb, SIRPα
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
  • BSI-001
    Modality / Target:
    mAb, HER2
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
    Partner
    ANKEBIO - China
  • BSI-075
    Modality / Target:
    mAb, PVRIG
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
  • BSI-500
    Modality / Target:
    bsAb, targets undisclosed
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
    Partner
    CTTQ - China
  • BSI-729
    Modality / Target:
    bsAb, targets undisclosed
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
  • BSI-712
    Modality / Target:
    ADC, LIV-1
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
  • BSI-709
    Modality / Target:
    ADC, CDH6
    MORE
    Solid Tumors
    • Preclinical
      Phase I
      Phase II
      Phase III
Copyright © 2022. Biosion All rights reserved. 苏ICP备2022027163号